先天性心脏病合并肺动脉高压相关生物标志物的研究新进展

New progress of biomarkers related to congenital heart disease complicated with pulmonary arterial hypertension

先天性心脏病合并肺动脉高压(CHD-PAH)是儿科肺动脉高压的重要类型,肺动脉高压影响右心功能,可导致右心室衰竭,是CHD-PAH患者死亡的主要原因。早期预测CHD-PAH患儿的不良预后对于积极改变相应的治疗策略,进而提高存活率至关重要。近年来,结缔组织生长因子、和肽素、内皮抑素及环状RNA等新兴的生物标志物被证明可对CHD-PAH患者的临床疗效及预后进行预测,对早期且准确的识别高危患者有重要作用。本文将通过讨论上述新型生物标志物与CHD-PAH的严重程度、疾病进展和临床疗效的相关性,以期为医师在临床诊治过程中运用相关生物标志物提供理论依据。

Congenital heart disease complicated with pulmonary arterial hypertension(CHD-PAH)is an important type of pediatric pulmonary arterial hypertension,which affects the right heart function and can lead to right ventricular failure,and is the main cause of death in patients with CHD-PAH.Early prediction of the poor prognosis in children with CHD-PAH is essential for the positive changes in the appropriate treatment strategies,then improvement of the survival.In recent years,emerging biomarkers such as connective tissue growth factor,copeptin,endostatin,and circular RNA are predictive of clinical outcomes and prognosis in CHD-PAH patients and important for early and accurate identification of high-risk patients.This article discusses the correlation between the above novel biomarkers and the severity,disease progression and clinical outcome of CHD-PAH to provide a theoretical basis for physicians to utilize the relevant biomarkers in clinical diagnosis and treatment.